Bortezomib treatment reduces the migration and invasive capacity of a cervical carcinoma HeLa cell line, which was associated with a decrease in the intracellular expression of MMP2 and MMP9 [36], and this is also observed in bortezomib treated chondrosarcoma cells [37]. This evidence concerns the gene MMP2 and cervical carcinoma.